Report summarizes molecular imaging study findings from M. Mansueto and co-researchers
2007 NOV 20 -- According to recent research published in the Quarterly Journal of Nuclear Medicine and Molecular Imaging, "The aim of this study was to evaluate the economic impact of the introduction of positron emission tomography (PET) in the clinical management of patients with known or suspected lung cancer through a cost-effectiveness analysis of different diagnostic strategiesIn Italy, 75 patients with known or suspected lung cancer were included in the study. Three different diagnostic strategies were compared: 1) baseline or traditional strategy, i.e. computed tomography (CT) alone; 2) strategy A, ie." "PET for indefinite CT; 3) strategy B, ie. PET for all. For each strategy expected costs and life expectancy, as measured by life year saved (LYS), were evaluated. Incremental cost-effectiveness ratio (ICER) was calculated to identify the most effective strategyCompared to the baseline strategy, the introduction of PET changed the clinical management in 40% of cases in strategy A and in 51% of cases in strategy B, with an optimization of the clinical management. Costs of strategy A (2 735.42 is an element of) and strategy B (2 984-52 is an element of) were, respectively, 8% and 18% higher than the baseline strategy (2 534.81 is an element of). LYS was 2.04 and 2.64 for strategy A and B, which were, respectively, 4% and 35% higher than the baseline strategy (1.96 LYS). The ICERs were 2 507.63 is an element of/LYS and 415.17 is an element of/LYS for strategy A and B, respectively," wrote M. Mansueto and colleagues. The researchers concluded: "Strategy A is dominated by strategy B, which is more expensive, but also more effectiveIn Italy, the introduction of PET in the clinical management of all patients with known or suspected lung cancer previously evaluated with CT is cost-effective and allows to gain 2.64 life years at an annual cost of about 415 is an element of." Mansueto and colleagues published their study in Quarterly Journal of Nuclear Medicine and Molecular Imaging (Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [F-18]fluorodeoxyglucose PET and CT comparison. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2007;51(3):224-234). For additional information, contact A. Grimaldi, Ist Science San Raffaele, Via Olgettina 60, I-20132 Milan, Italy. The publisher's contact information for the Quarterly Journal of Nuclear Medicine and Molecular Imaging is: Edizioni Minerva Medica, Corso Bramante 83-85 International Journals Dept., 10126 Turin, Italy. Keywords: Italy, Milan, Molecular Imaging, Nanotechnology. This article was prepared by Medical Imaging Law Week editors from staff and other reports. Copyright 2007, Medical Imaging Law Week via NewsRx.com.
|
